Instructions for Nomides (Oseltamivir) capsules
English product name
Nomides
Release Form
caps. 30 mg: 5, 10, 20 or 30 pcs
caps. 45 mg: 5, 10, 20 or 30 pcs
caps. 75 mg: 5, 10, 20 or 30 pcs
Description Oseltamivir
The capsules are solid gelatine capsules №3, the body is white in color, the cap is white in color; the contents of the capsules are white or white with a yellowish shade of powder.
1 cap.
oseltamivir phosphate 39.4 mg
which corresponds to oseltamivir content 30 mg
Auxiliary substances: silica colloidal (aerosyl) - 6 mg, copovidone - 3.6 mg, pregelatinized starch - 65.6 mg, sodium croskarmellose - 1.84 mg, sodium stearyl fumarate - 0.92 mg, talc - 2.64 mg.
Capsule body composition: titanium dioxide - 2%, gelatin - up to 100%.
Capsule cap composition: titanium dioxide - 2%, gelatin - up to 100%.
ATC codes
J05AH02 Oseltamivir
Clinical-pharmacological groups / Group affiliation Nomides
Antiviral drug
Active substance
oseltamivir
Pharmaco-therapeutic group Nomides
Antiviral agent
Pharmacological effect Oseltamivir
Antiviral drug. Neuraminidase is a glycoprotein that catalyzes the breakdown of the relationship between the terminal sialic acid and sugar, thereby contributing to the spread of the virus in the respiratory tract (the release of virions from the infected cell and the entry into the respiratory tract epithelial cells, preventing the inactivation of the virus by the epithelial mucus). Oseltamivir carboxylate acts outside cells and competitively inhibits neuraminidase of the virus. Inhibits the growth of the influenza virus in vitro and suppresses the replication of the virus and its pathogenicity in vivo. Reduces the release of influenza A and B viruses from the body.
Does not affect antibody production in response to the introduction of inactivated influenza vaccine.
The resistance frequency of clinical isolates of the virus is 2%.
Testimony Oseltamivir
Influenza A and B.
Method of use, course and dosage Oseltamivir
They are taken inside regardless of their intake of food.
Treatment should begin no later than 2 days from the onset of symptoms at a dose of 75 mg twice/day within five days. A dose increase of more than 150 mg/day does not enhance the effect.
For the prophylaxis of influenza types A and B in adults - 75 mg 1-2 times/day for 6 weeks. (during the flu epidemic). The maximum daily dose for adults is 150 mg.
In patients with a QC of less than 30 ml/min, the dose is reduced to 75 mg once/day for five days.
- Nosology Nomides (ICD codes)
- J10
- Influenza caused by an identified seasonal influenza virus
